Nayak L, et al. Future Oncol. 2026;15:1751-57.

This publication describes the background, rationale, and study design of the ongoing phase III IGNITE study evaluating tirabrutinib versus rituximab plus temozolomide in patients with relapsed or refractory primary central nervous system lymphoma (PCNSL). The primary endpoint is progression-free survival, with overall response rate and overall survival as key secondary endpoints.

You can access the publication here.